Results 81 to 90 of about 3,710 (152)

Soluble guanylate cyclase stimulator riociguat improves spatial memory in mice via peripheral mechanisms

, 2022
Soluble guanylate cyclase (sGC) - cyclic guanosine monophosphate (cGMP) signalling is important for healthy memory function and a healthy vascular system.
Arjan Blokland, Elentina K. Argyrousi, Danielle A.J. Mulder-Jongen, Argyrousi, Elentina K, van Goethem, Nick P, Ramaekers, Johannes G., Jos Prickaerts, Mulder-Jongen, Danielle A J, Nick P. van Goethem, Johannes G. Ramaekers, Dean Paes, van Hagen, Britt T J, Pim R.A. Heckman, Blokland, Arjan, Harald H.H.W. Schmidt, Schmidt, Harald H.H.W., Britt T.J. van Hagen, Nelissen, Ellis, Paes, Dean, Ellis Nelissen, Heckman, Pim R.A.; id_orcid, Prickaerts, Jos, Heckman, Pim R.A.   +22 more
core   +1 more source

Riociguat pretreatment in patients with chronic thromboembolic pulmonary hypertension

Question Whether pretreatment with vasodilators reduces balloon pulmonary angioplasty (BPA)-related complications and achieves better outcomes in patients with inoperable chronic thromboembolic pulmonary ...
Yoshitake Fukuda, Hiroto Shimokawahara, Hiromi Matsubara, Kimi Sato, Soichiro Kobashi, Misaki Kanezawa   +5 more
core   +1 more source

Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways

Biomedicines
Background/Objectives: Pulmonary hypertension is a progressive disease leading to right heart failure. One treatment strategy is to induce vasodilation via the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate (NO–sGC–cGMP) signaling ...
Katharina Nubbemeyer, Julia Krabbe, Svenja Böll, Anna Michely, Sebastian Kalverkamp, Jan Spillner, Christian Martin   +6 more
doaj   +1 more source

Riociguat prevents hyperoxia-impaired alveolarization.

, 2018
(A) H & E stained lung histology. Hyperoxia exposure in the presence of placebo decreased radial alveolar count (RAC) (B) and increased mean linear intercept (MLI) (C) as compared with normoxia. Administration of riociguat increased RAC and decreased MLI
Ronald Zambrano (5497406), Younghye Moon (200726), Shu Wu (492135), Shihua Luo (5497415), Yong Bao (296790), Luqing Wang (5257895), Merline Benny (5497403), Justin Percival (5497412), Ling Qin (68169), Fredrick Dapaah-Siakwan (5497409), Matthew R. Duncan (5497421), Keyur Donda (5497400), Karen Young (833929), Ruben Vaidya (5497418)   +13 more
core   +1 more source

Riociguat for pulmonary arterial hypertension associated with congenital heart disease

, 2015
The Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (PATENT-1) was a randomised, double-blind, placebo-controlled phase III trial evaluating riociguat in patients with pulmonary arterial hypertension (PAH).
Apitz, Christian, Beghetti, Maurice, Ghofrani, Hossein-Ardeschir, Fritsch, Arno, Saleh, Soundos, Ivy, Dunbar, Weimann, Gerrit, Rosenkranz, Stephan, Frey, Reiner   +8 more
core   +1 more source

Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series

Pulmonary Circulation, 2018
Adults with sickle cell disease can develop pulmonary hypertension from a multitude of etiologies. Classified as WHO Group 5, there are no therapies approved for the treatment of sickle cell disease-pulmonary hypertension.
Nargues A. Weir, Anna Conrey, Denise Lewis, Alem Mehari   +3 more
doaj   +1 more source

Improved process for preparation of crystalline Modification-I of Riociguat [PDF]

The present publication relates to a process for preparation of crystalline Modification-I of ...
Anonymous,
core   +1 more source

Better efficacy of sequential combination with balloon pulmonary angioplasty after long‐term riociguat for patients with inoperable chronic thromboembolic pulmonary hypertension

Pulmonary Circulation
The present study aimed to evaluate the efficacy of long‐term riociguat sequentially combined with balloon pulmonary angioplasty (BPA) for patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
Wei Wang, Jianfeng Wang, Suqiao Yang, Tuguang Kuang, Yidan Li, Juanni Gong, Yuanhua Yang   +6 more
doaj   +1 more source

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)

, 2015
Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).
Simonneau G, Mayer E., Ghofrani HA, Wang C, Jansa P6, D'ARMINI, ANDREA MARIA, Grimminger F, Hoeper MM, Wilkins M, Colorado P, Fritsch A, Kim NH, Davie N   +12 more
core   +1 more source

Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy

European Respiratory Review, 2009
The prognosis for patients with pulmonary hypertension remains poor despite recent treatment advances, and there is a need for therapies with new modes of action.
H. A. Ghofrani, F. Grimminger
doaj